Seven patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2038. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2038
Next term end
7
Patent families
When these terms end
Each bar runs from grant to computed term end. 2020 to 2042.
US 10,624,771
Stent Delivery System, Corresponding Flow Diversion Device, and Assembly Method of Flow Diversion Device
Mar 8, 2038
20252030203520402042
4 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2038 · High confidence
Also notable
Ends Oct 2039 · High confidence
Also notable
Ends Feb 2042 · High confidence
Stent Delivery System, Corresponding Flow Diversion Device, and Assembly Method of Flow Diversion Device
US 10,624,771
The most cited patent in this portfolio, cited by 89 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2038.
Neurovascular Stent
US D1,046,151
The newest of the three, granted 2024. It anchors the portfolio to 2039, later than anything else here.
Braided Tube Formation Apparatus and Methods of Use
US 11,753,755
Granted 2023. Computed term ends 2042.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for Stent Retriever with Radiopaque Members (US 11,707,290) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 1 fee due Mar 12, 2027The maintenance fee for Braided Tube Formation Apparatus and Methods of Use (US 11,753,755) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
- 1 fee due Apr 30, 2027The maintenance fee for Liquid Embolic Compositions (US 11,801,058) comes due Apr 30, 2027. Unpaid by Nov 1, 2027, it lapses early.
- 1 fee due Oct 21, 2027The maintenance fee for Stent Delivery System, Corresponding Flow Diversion Device, and Assembly Method of Flow Diversion Device (US 10,624,771) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,624,771 | Stent Delivery System, Corresponding Flow Diversion Device, and Assembly Method of Flow Diversion Device In force · High confidence | In force | High confidence | |
| US D1,046,151 | Neurovascular Stent In force · High confidence | In force | High confidence | |
| US 11,134,954 | Braided Embolization Apparatus In force · High confidence | In force | High confidence | |
| US 11,707,290 | Stent Retriever with Radiopaque Members In force · High confidence | In force | High confidence | |
| US 11,660,217 | Stent Delivery Component, Stent Delivery System and Stent System In force · High confidence | In force | High confidence | |
| US 11,753,755 | Braided Tube Formation Apparatus and Methods of Use In force · High confidence | In force | High confidence | |
| US 11,801,058 | Liquid Embolic Compositions In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 4 applications pending · 3 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.